Global neuropathic pain treatment market value to increase from $2.58 billion in 2012 to $3.53 billion by 2022
With seven promising neuropathic pain (NP) treatments expected to be launched in the coming years, the NP therapeutics market value — covering painful diabetic neuropathy, postherpetic neuralgia and trigeminal neuralgia — is forecast to increase from $2.58 billion in 2012 to $3.53 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 3.19%, says research and consulting firm GlobalData.
According to the company’s latest report*, seven novel pipeline drugs targeting these three indications will enter the market before 2022. These include Daiichi Sankyo’s DS-5565, Convergence’s CNV-2197944, Grünenthal’s Cebranopadol and Impax’s Eladur. GlobalData expects the sales of these pipeline therapies to account for 23.8% of the global NP market by 2022.
Sally Chege, Ph.D., GlobalData’s Analyst covering Neurology, says: “Although many of the available drugs offer some degree of efficacy in terms of pain relief, there still remains vast room for improvement in efficacy, safety, drug delivery, and dosing convenience.
“Furthermore, all three market-leading therapies, Pfizer’s Lyrica, Eli Lilly’s Cymbalta and Endo Health’s Lidoderm, will lose patent protection over the forecast period, therefore increasing the risk of generic erosion.”
GlobalData believes that there are opportunities for companies to enter the NP market through the development of novel drugs, provided that their product offerings target some of these unmet needs.
However, as Chege continues: “Steep research and development costs, as well as the high failure rate of pain medications in NP clinical trials, have led many larger pharmaceutical companies to deprioritize the development of new NP therapies.”
*PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.